revenu significantli ep
also pdl adjust acelrx asset fair valu pdl continu pursu
strateg goal build portfolio activ invest high growth compani
acquir evofem dcf analysi suggest pdl share fairli
valu remain market perform
pdl report revenu neg significantli estim
tekturna/rasilez revenu includ
ex-u in-lin estim lensar laser system product
sale estim pdl report royalti right chang
fair valu revenu well pdl receiv
q/q y/i net cash royalti though off-set
account charg chang fair valu account charg mostli relat
non-cash write-down acelrx royalti quarter pdl
book revenu interest loan miss estim queen
patent expir pdl report royalti tysabri product manufactur
expir patent ep pdl end
cash share repurchas program author
septemb pdl repurchas juli pdl use final
remain repurchas program thu conclud pdl
provid revenu guidanc noden product lensar
product cash royalti adjust est consist
new revenu estimate ep estimate vs prior est
respect dcf-base price target remain
april pdl announc enter equiti invest evofem
bioscienc could invest total two tranch
first tranch provid april second close
june pdl own approx evofem evofem focus develop product
women sexual reproduct health evofem lead product amphora on-
demand non-hormon contracept gel follow initi submiss fda
amphora nda receiv complet respons letter due discrep
efficaci result trial site russia vs territori evofem subsequ
conduct addit studi ampow use site trial met
primari endpoint prevent pregnanc data report decemb
evofem plan resubmit nda amphora anticip product launch
pleas see page report import disclosur
pdl strateg goal build portfolio activ invest high growth
compani away biotech financi servic organ focus loan
sell tekturna tekturna gener sale began face
gener competit begin march pdl strategi make
activ invest compani innov late clinical-stag earli commercial-
stage therapeut attract revenu growth potenti april pdl announc
equiti invest follow second tranch
invest june evofem women health compani develop on-demand
non-hormon contracept gel call amphora expect launch
dcf analysi suggest pdl worth approxim
releas top-lin data evofem
prevent chlamydia
re-submiss nda amphora
possibl addit activ invest
tekturna sale declin
pdl continu receiv
royalti revenu
pdl invest new asset
project
pdl receiv
royalti revenu
pdl invest asset gener
tekturna sale declin faster
pdl acquir asset gener
initi pdl establish domin intellectu properti posit human
monoclon antibodi mab monet technolog via royalty-bear licens
drug herceptin xolair avastin lucenti perjeta kadcyla gazyva
roch tysabri howev expir queen patent
exhaust pre-expiri inventori pdl royalti product end queen
patent expir pdl deploy acquir addit income-gener
asset notabl juli pdl acquir noden manufactur market sell tekturna
tekturna hct brand rasilez rasilez hct outsid novarti
pdl strategi make activ invest compani innov late clinical-
stage earli commercial-stag therapeut attract revenu growth potenti
june noden wholli own subsidiari pdl receiv paragraph iv notic
letter disclos submit anda fda
manufactur gener version tekturna tablet
letter certifi noden orange-book list patent expir
februari june noden enter settlement agreement
anchen accord agreement noden grant anchen non-exclus non-
transfer royalty-fre licens sell gener tekturna exchang anchen agre
delay launch gener tekturna march pdl expect anchen
sole gener competitor tekturna
march pdl launch author gener tekturna prasco laboratori
effect compet gener enter market manag estim
brand tekturna ag held market end pdl previous
discontinu contract sale forc tekturna transit non-person email
direct mail tele-sal promot tekturna archer healthcar pdl guid
noden revenu base current trend estim increas
strateg goal build portfolio activ
invest high growth compani away biotech financi servic
organ focus loan royalti acquisit initi pdl establish
domin intellectu properti posit human monoclon
antibodi mab monet technolog via royalty-bear licens
drug herceptin xolair avastin lucenti perjeta kadcyla gazyva
roch tysabri howev expir queen patent
exhaust pre-expiri inventori pdl royalti product
end queen patent expir pdl deploy acquir
addit income-gener asset notabl juli pdl acquir noden
manufactur market sell tekturna tekturna hct brand rasilez
rasilez hct outsid novarti tekturna indic
treatment hypertens tekturna gener sale
began face gener competit begin march pdl
strategi make activ invest compani innov late
clinical-stag earli commercial-stag therapeut attract revenu
growth potenti april pdl announc equiti invest
evofem bioscienc follow second tranch invest june
evofem women health compani develop on-demand non-
hormon contracept gel call amphora expect launch
dcf analysi suggest pdl worth approxim
pdl appear fairli valu remain market perform
evofem re-submit nda amphora prevent pregnanc
evofem releas top-lin data phase iib trial amphora prevent chlamydia
evalu opportun make activ invest
like pdufa date amphora
commerci launch amphora prevent pregnanc
cowen compani
cowen compani
partner queen patentsdepom cerdelga servic nol sprovis valu royaltiesdiscount growth npv royalty/licens pdl balanc loan equiti cowen
cowen compani
cowen compani
queen right chang fair gener incom net incom net incom share share queen right chang fair gener incom net incom net incom share share cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
pdl revenu depend sale product royalti receiv
biopharmaceut product licens patent own pdl interest
incom loan pdl made predict futur revenu biopharmaceut
product difficult chang regulatori commerci competit environ
alter prospect product product sale advers affect loss
patent regulatori exclus moreov pdl face credit risk loan portfolio
